BioPharma Resources

Drug Trial Radar · NCT01422876

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control

Last checked: Nov 19, 2026Latest source record: Apr 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,405

Actual

Start

Aug 2011

Primary completion

Sep 2013

Study completion Sep 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • high dose FDCDrug

    once daily

  • BI 10773 high doseDrug

    once daily

  • high dose FDC placeboDrug

    once daily

  • low dose FDC placeboDrug

    once daily

  • high dose FDC placeboDrug

    once daily

  • high dose FDC placeboDrug

    once daily

  • low dose FDC placeboDrug

    once daily

  • low dose FDC placeboDrug

    once daily

  • high dose BI 10773 placeboDrug

    once daily

  • low dose FDCDrug

    once daily

  • high dose FDC placeboDrug

    once daily

  • BI 10773 low doseDrug

    low dose once daily

  • high dose BI 10773 placeboDrug

    once daily

  • high dose BI 10773 placeboDrug

    once daily

  • linagliptinDrug

    once daily

  • low dose FDC placeboDrug

    once daily

  • linagliptin placeboDrug

    once daily

  • BI 10773 low dose placeboDrug

    once daily

  • linagliptin placeboDrug

    once daily

  • low dose BI 10773 placeboDrug

    once daily

  • linagliptin placeboDrug

    once daily

  • high dose BI 10773 placeboDrug

    once daily

  • BI 10773 low dose placeboDrug

    once daily

  • low dose BI 10773 placeboDrug

    once daily

  • linagliptin placeboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background PatientsTime frame: Baseline and 24 weeks
  2. Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive PatientsTime frame: Baseline and 24 weeks

Locations

211 sites in 22 countries. Site status is shown where the registry gives one.

  • 1275.1.01103 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1275.1.01107 Boehringer Ingelheim Investigational Site

    Foley, Alabama

  • 1275.1.01043 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1275.1.01066 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1275.1.01047 Boehringer Ingelheim Investigational Site

    Pell City, Alabama

  • 1275.1.01089 Boehringer Ingelheim Investigational Site

    Mesa, Arizona

  • 1275.1.01064 Boehringer Ingelheim Investigational Site

    Tempe, Arizona

  • 1275.1.01028 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1275.1.01086 Boehringer Ingelheim Investigational Site

    Cerritos, California

  • 1275.1.01067 Boehringer Ingelheim Investigational Site

    Chula Vista, California

  • 1275.1.01109 Boehringer Ingelheim Investigational Site

    Encino, California

  • 1275.1.01012 Boehringer Ingelheim Investigational Site

    Fresno, California

  • 1275.1.01050 Boehringer Ingelheim Investigational Site

    Harbor City, California

  • 1275.1.01056 Boehringer Ingelheim Investigational Site

    Huntington Park, California

  • 1275.1.01021 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 1275.1.01024 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1275.1.01112 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1275.1.01083 Boehringer Ingelheim Investigational Site

    Oceanside, California

  • 1275.1.01071 Boehringer Ingelheim Investigational Site

    San Dimas, California

  • 1275.1.01044 Boehringer Ingelheim Investigational Site

    Tustin, California

  • 1275.1.01078 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1275.1.01124 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1275.1.01010 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1275.1.01048 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1275.1.01073 Boehringer Ingelheim Investigational Site

    Gainesville, Florida

  • 1275.1.01063 Boehringer Ingelheim Investigational Site

    Hialeah, Florida

  • 1275.1.01077 Boehringer Ingelheim Investigational Site

    Hialeah, Florida

  • 1275.1.01090 Boehringer Ingelheim Investigational Site

    Inverness, Florida

  • 1275.1.01054 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1275.1.01092 Boehringer Ingelheim Investigational Site

    Maitland, Florida

  • 1275.1.01065 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1275.1.01110 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1275.1.01040 Boehringer Ingelheim Investigational Site

    Miami Beach, Florida

  • 1275.1.01025 Boehringer Ingelheim Investigational Site

    Miami Lakes, Florida

  • 1275.1.01094 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1275.1.01068 Boehringer Ingelheim Investigational Site

    Ormond Beach, Florida

  • 1275.1.01051 Boehringer Ingelheim Investigational Site

    Pembroke Pines, Florida

  • 1275.1.01079 Boehringer Ingelheim Investigational Site

    Port Orange, Florida

  • 1275.1.01117 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1275.1.01039 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.